Incannex Healthcare stock tumbles after filing $100M offering
James Paul Lang, a director at OptimizeRx Corp (NASDAQ:OPRX), has acquired a substantial amount of the company’s common stock. According to a recent SEC filing, Lang purchased 321,408 shares on March 14, 2025, at a weighted average price of $7.6033 per share. The timing of this purchase appears strategic, as InvestingPro data shows the stock has surged 37% in the past week, with analyst price targets ranging from $6 to $16. The total value of this transaction amounts to approximately $2.44 million. The shares were bought in multiple transactions, with prices ranging from $7.18 to $7.80. Following this acquisition, Lang holds 389,452 shares in the company directly. The company, currently valued at $159.62M, maintains good financial health according to InvestingPro metrics, with liquid assets exceeding short-term obligations. Discover more insights and 10+ additional ProTips about OPRX with an InvestingPro subscription.
In other recent news, OptimizeRx Corp reported its Q4 2024 financial results, highlighting a 14% year-over-year revenue increase to $32.3 million. Despite a small net loss of $100,000, the company significantly improved from a $4.1 million loss in Q4 2023. OptimizeRx’s adjusted EBITDA rose to $8.8 million, and its gross margin expanded to 68.2% from 62.9% the previous year. The company plans to transition to a subscription-based data services model, aiming for more predictable revenue streams. Analysts from firms like William Blair and B. Riley have shown interest in these developments, with discussions around the company’s gross margin expansion and strategic focus on customer centricity. OptimizeRx also announced a strategic review of its business processes, aiming to position itself to capitalize on the growing demand for dynamic audience solutions in the pharmaceutical sector. The company anticipates achieving a Rule of 40 status within three to five years, projecting nearly 10% revenue growth and maintaining 100% net revenue retention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.